13D Filings
Cocrystal Pharma, Inc.
COCP
Amendment
Ownership

10.60%

Total Shares

1,382,873

Issuer CIK

1412486

CUSIP

19188J409

Event Date

Sep 29, 2025

Accepted

Oct 2, 2025, 06:29 PM

Reporting Persons (2)
NameType% of ClassAggregateSole VotingShared Voting
Phillip Frost, M.D.
Individual
10.60%1,382,8731,382,8730
Frost Gamma Investments Trust
Other
10.10%1,319,8381,319,8380
Disclosure Items (7)

Security Title

Common Stock, par value $0.001 per share

Issuer Name

Cocrystal Pharma, Inc.

Issuer Address

19805 N. CREEK PARKWAY, BOTHELL, WA, 98011

Filing Persons

This Amendment is filed on behalf of Phillip Frost, M.D. and FGIT (together, the "Reporting Persons").

Business Address

The principal business address of the Reporting Persons is 4400 Biscayne Boulevard, Miami, Florida 33137.

Convictions

During the last five years, none of the Reporting Persons (or their directors, officers, or controllers, if applicable) have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding were or are subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violations with respect to such laws.

Citizenship

Dr. Frost is a citizen of the United States of America. FGIT was organized in the State of Florida.

On August 21, 2025, the Reporting Person acquired 13,550 shares of the Issuer's common stock in connection with the vesting of restricted stock units. On September 30, 2025, the Reporting Person acquired 1,693 shares of the Issuer's common stock in connection with the vesting of restricted stock units.

The Reporting Persons acquired the shares of common stock for investment purposes. On August 21, 2025, the Reporting Person acquired 13,550 shares of the Issuer's common stock upon vesting of restricted stock units. On September 30, 2025, the Reporting Person acquired 1,693 shares of the Issuer's common stock in connection with the vesting of restricted stock units. These securities are held by FGIT, of which Phillip Frost, MD is the trustee. Frost Gamma L.P. is the sole and exclusive beneficiary of FGIT. Dr. Frost is one of two limited partners of Frost Gamma L.P. The general partner of Frost Gamma L.P. is Frost Gamma, Inc., and the sole shareholder of Frost Gamma, Inc. is Frost-Nevada Corporation. Dr. Frost is the sole shareholder of Frost-Nevada Corporation. Dr. Frost disclaims beneficial ownership of the securities held by FGIT except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that Dr. Frost is the beneficial owner of these securities for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.

Percentage of Class

The beneficial ownership percentages disclosed below are based on 13,039,348 shares of common stock outstanding as of September 29, 2025. Dr. Frost is the beneficial owner of 1,382,873 shares of common stock representing 10.6% of the shares outstanding of the Issuer, including (i) 1,319,838 shares of common stock held by FGIT, (ii) 15,243 shares of the Issuer's common stock held by the Reporting Person and (iii) 47,792 shares of common stock issuable upon exercise of vested options. Dr. Frost is the trustee of FGIT. Frost Gamma Limited Partnership is the sole and exclusive beneficiary of FGIT. Dr. Frost is one of two limited partners of Frost Gamma Limited Partnership. Dr. Frost is the sole shareholder of Frost-Nevada Corporation, which is the sole shareholder of Frost Gamma, Inc., the general partner of Frost Gamma Limited Partnership. As a result of the foregoing, Dr. Frost may be deemed the beneficial owner of the shares of common stock held by FGIT. Dr. Frost disclaims beneficial ownership of the securities held by FGIT except to the extent of any pecuniary interest therein. Dr. Frost has sole dispositive power with respect to 47,792 shares of common stock issuable upon exercise of vested options.

Number of Shares

The Reporting Persons have voting and dispositive power over the Issuer's securities as described above in Item 5(a).

Transactions

Except as described in this Schedule 13D under Item 3 above, the Reporting Persons did not engage in any transactions in shares of the Company's common stock during the past 60 days.

Shareholders

Not Applicable.

Date of 5% Ownership

Not Applicable.

Not Applicable.

None.

Cocrystal Pharma, Inc. — Schedule 13D | 13D Filings